Nurko S, Garcia-Aranda J A, Worona L B, Zlochisty O
Department of Gastroenterology and Nutrition Hospital Infantil De Mexico "Federico Gomez," Mexico City, Mexico.
J Pediatr. 2000 Jan;136(1):35-40. doi: 10.1016/s0022-3476(00)90046-5.
To determine whether cisapride is effective in the treatment of children with constipation.
Double-blind, placebo-controlled study in which children with chronic constipation were randomly assigned to treatment with cisapride or placebo for 12 weeks.
Forty children were enrolled, and 36 completed the therapy. Treatment successes occurred in 13 of 17 (76%) subjects in the cisapride group and 8 of 19 (37%) subjects in the placebo group (P <.03). The odds ratio for response after cisapride administration was 8.2 times higher (95% CI 1.3 to 49.4). During cisapride therapy, there was a significant improvement in number of spontaneous bowel movements per week (from 0.9 +/- 0.1 to 4.1 +/- 1.1), and there was a significant decrease in number of fecal soiling episodes per day (1.8 +/- 0.5 to 0.08 +/- 0.4), percent with encopresis (82% vs 23%), number of laxative doses per week (from 10.3 +/- 2.6 to 0.8 +/- 0.6), percent using laxatives (77% to 24%), and total gastrointestinal transit time (from 115.0 +/- 3.7 hours to 77.0 +/- 11.1 hours). With placebo, there were no significant changes in the number of spontaneous bowel movements (from 1.0 +/- 0.8 to 2.2 +/- 0.6), percent with encopresis (74% vs 47%), or total gastrointestinal transit time (from 112.5 +/- 4.9 hours to 95.4 +/- 9.8 hours); but there was a significant decrease in number of fecal soiling episodes per day (from 1.3 +/- 0.4 to 0.4 +/- 0.2) and number of laxative doses used per week (from 11.5 +/- 2.9 to 2.05 +/- 0.7). The final number of spontaneous bowel movements, fecal soiling episodes, laxatives used, or percent patients with encopresis was not different when patients receiving cisapride were compared with those receiving placebo.
Cisapride was effective in the treatment of children with constipation.
确定西沙必利治疗儿童便秘是否有效。
双盲、安慰剂对照研究,将慢性便秘患儿随机分为西沙必利治疗组或安慰剂治疗组,治疗12周。
40名儿童入组,36名完成治疗。西沙必利组17名受试者中有13名(76%)治疗成功,安慰剂组19名受试者中有8名(37%)治疗成功(P<.03)。服用西沙必利后反应的优势比高8.2倍(95%可信区间1.3至49.4)。在西沙必利治疗期间,每周自发排便次数显著改善(从0.9±0.1次增至4.1±1.1次),每天大便失禁发作次数显著减少(从1.8±0.5次减至0.08±0.4次),有大便失禁的百分比(82%对23%),每周泻药剂量(从10.3±2.6次减至0.8±0.6次),使用泻药的百分比(77%至24%),以及全胃肠通过时间(从115.0±3.7小时减至77.0±11.1小时)。使用安慰剂时,自发排便次数(从1.0±0.8次增至2.2±0.6次)、有大便失禁的百分比(74%对47%)或全胃肠通过时间(从112.5±4.9小时减至95.4±9.8小时)无显著变化;但每天大便失禁发作次数(从1.3±0.4次减至0.4±0.2次)和每周使用泻药剂量(从11.5±2.9次减至2.05±0.7次)有显著减少。将接受西沙必利治疗的患者与接受安慰剂治疗的患者进行比较时,最终的自发排便次数、大便失禁发作次数、使用的泻药或有大便失禁的患者百分比并无差异。
西沙必利治疗儿童便秘有效。